Lapatinib D4 is a deuterated derivative of Lapatinib, which is a small molecule kinase inhibitor used in the treatment of breast cancer. Lapatinib D4 is a potent inhibitor of the receptor tyrosine kinases (RTKs) ErbB1 and ErbB2, which are overexpressed in many breast cancer cases. The deuterated form of Lapatinib has been used in pharmacokinetic studies to help researchers understand the metabolism and distribution of the drug within the body. This information can be useful in optimizing dosing regimens and reducing toxicity.
Lapatinib D4 has a molecular formula of C29H28ClFN4O4S2D4 and a molecular weight of 613.19 g/mol. The deuterated form has four extra hydrogen atoms replaced with deuterium atoms, which can affect the drug's physical and chemical properties. The drug is a yellow to brownish-yellow powder that is soluble in dimethyl sulfoxide (DMSO) and ethanol.
The recommended dosage of Lapatinib D4 varies depending on the patient's weight and the severity of their condition. The drug is usually administered orally in tablet form, and it is important to follow the prescribed dosing schedule to achieve optimal therapeutic effects. Common side effects of Lapatinib D4 may include fatigue, diarrhea, nausea, vomiting, and skin rash. Patients should be monitored closely for signs of toxicity and drug interactions. Overall, Lapatinib D4 is an important tool in the fight against breast cancer, and its unique chemical properties make it a valuable asset in pharmacological research.